Table 2 Univariate and multivariate analysis of prognostic factors in patients (PFS)
Parameters | Univariate | Multivariate | ||||||
|---|---|---|---|---|---|---|---|---|
Median (months) | 95% CI | HR | 95% CI | p-value | HR | 95% CI | p-value | |
Age | ||||||||
≤ 65 | 9.9 | 7.8–12.0 | 0.95 | 0.54–1.66 | 0.862 | |||
> 65 | 8.1 | 1.2–15.0 | ||||||
Sex | ||||||||
Male | 11.6 | 7.2–16.1 | 0.66 | 0.37–1.16 | 0.15 | |||
Female | 6.7 | 3.2–10.2 | ||||||
Smoking statusa | ||||||||
Smoker | 14.8 | 10.1–19.5 | 0.54 | 0.25–1.16 | 0.113 | |||
Never smoker | 8.1 | 5.5–10.6 | ||||||
Performance status, PS | ||||||||
PS 2 | 9.9 | 8.4–11.4 | 0.94 | 0.52–1.69 | 0.826 | |||
PS 3/4 | 6.2 | 5.0–7.5 | ||||||
Mutation | 0.446 | |||||||
L858R | 8.4 | 5.2–11.5 | 0.77 | 0.33–1.80 | 0.548 | |||
19del | 10.2 | 7.3–13.1 | 0.59 | 0.25–1.41 | 0.235 | |||
Uncommon | 3.5 | 0.5–6.6 | ||||||
Starting dose | ||||||||
40 mg | 10.8 | 8.6–13.1 | 0.55 | 0.31–0.98 | 0.043 | 0.92 | 0.49–1.75 | 0.806 |
30 mg | 6.7 | 1.9–11.5 | ||||||
Metastatic sites | ||||||||
Lung | ||||||||
Yes | 8.1 | 5.5–10.6 | 1.41 | 0.81–2.46 | 0.222 | |||
No | 9.9 | 8.5–11.3 | ||||||
Liver | ||||||||
Yes | 3.1 | 0.0–13.3 | 1.94 | 1.02–3.69 | 0.044 | 2.17 | 1.11–4.26 | 0.023 |
No | 9.9 | 6.5–13.3 | ||||||
Brain | ||||||||
Yes | 9.8 | 7.6–12.0 | 1.16 | 0.66–2.04 | 0.615 | |||
No | 8.6 | 5.8–11.5 | ||||||
Bone | ||||||||
Yes | 9.8 | 8.1–11.5 | 0.65 | 0.38–1.14 | 0.133 | |||
No | 5.9 | 1.4–10.2 | ||||||
Pleura | ||||||||
Yes | 8.1 | 0.8–15.3 | 1.92 | 1.07–3.45 | 0.03 | 1.58 | 0.84–2.98 | 0.157 |
No | 10.2 | 6.8–13.6 | ||||||
Adrenal gland | ||||||||
Yes | 8.6 | 0.0–21.1 | 1.13 | 0.35–3.64 | 0.842 | |||
No | 8.9 | 5.4–12.3 | ||||||
Distant lymphadenopathy | ||||||||
Yes | 6.7 | 0.0–15.9 | 1.91 | 0.74–4.94 | 0.183 | |||
No | 8.9 | 7.0–10.8 | ||||||
Dose reduction/interruption | ||||||||
Yes | 11.6 | 9.0–14.3 | 0.65 | 0.36–1.16 | 0.143 | |||
No | 6.2 | 0. 0–12.7 | ||||||
Discontinuation, AE-related | ||||||||
Yes | 6.7 | 0.6–12.8 | 0.64 | 0.20–2.07 | 0.457 | |||
No | 8.9 | 6.9–10.8 | ||||||
Clinical tumor response | < 0.001 | < 0.001 | ||||||
CR/PR | 11.8 | 9.2–14.4 | 0.05 | 0.02–0.13 | < 0.001 | 0.05 | 0.02–0.13 | < 0.001 |
SD | 18.4 | 4.7–32.1 | 0.04 | 0.01–0.14 | < 0.001 | 0.05 | 0.01–0.19 | < 0.001 |
PD/NA | 1.4 | 0.9–1.8 | ||||||
BMI | 1.05 | 0.97–1.13 | 0.244 | |||||
BSA | 0.1 | 0.01–2.02 | 0.132 | |||||